Retatrutide × VANDL Labs - Lab Test, March 2026
Test results
About this test
This independent HPLC-UV/VIS lab test confirms Retatrutide 20mg from VANDL Labs at 99.80% purity. Quantity analysis measured 20.29 mg, with endotoxin levels at <5.00 EU/mg and sterility confirmed (USP <71> passed, no growth detected). The analysis was conducted by Vanguard Laboratory on March 16, 2026.
Retatrutide is a triple GLP-1/GIP/GCG receptor agonist researched for metabolic regulation, weight management, glycemic control, and glucose homeostasis. It is studied for its synergistic effects on multiple signaling pathways for comprehensive metabolic and anti-aging effects. The 99.80% purity indicates high-quality synthesis with minimal contamination, and passing endotoxin and sterility testing confirms safety compliance.
The full certificate of analysis is available for download on this page.
Certificate of analysis
Have you tested this peptide?
Submit your third-party lab test to help the community verify purity claims. Every report is reviewed before publication.
Community discussion
No comments yet. Sign in to be the first to discuss this test.